Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 1.85B +86.9% |
| Revenue (ttm) | 172.35M +627.8% |
| Net Income | -285.42M |
| EPS | -3.29 |
| Shares Out | 88.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,316,596 |
| Open | 21.39 |
| Previous Close | 21.39 |
| Day's Range | 20.64 - 21.75 |
| 52-Week Range | 8.58 - 25.59 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 38.69 (+84.24%) |
| Earnings Date | Apr 30, 2026 |
About SNDX
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination... [Read more]
Financial Performance
In 2025, Syndax Pharmaceuticals's revenue was $172.35 million, an increase of 627.84% compared to the previous year's $23.68 million. Losses were -$285.42 million, -10.46% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $38.69, which is an increase of 84.24% from the latest price.
News
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will rep...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1,...
Syndax Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Two leading oncology products are driving strong sales and market adoption, with Revuforj becoming standard of care in acute leukemia and Niktimvo expanding in chronic GVHD. Combination strategies, robust clinical development, and disciplined financial management support continued growth, while new indications and collaborations are advancing the pipeline.
Syndax Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Strong commercial launches for two products are driving revenue growth and market expansion, with pivotal studies underway to enter the frontline AML market and new indications like myelofibrosis and IPF. Physician education and scientific engagement remain priorities, while profitability is expected soon due to robust sales and controlled expenses.
Syndax Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Two commercial products have achieved rapid market penetration and record first-year sales, with Revuforj and Niktimvo driving growth in AML and chronic GVHD. Expanding indications, increasing therapy duration, and robust clinical pipeline support a multi-billion dollar market opportunity and a path to profitability.
Syndax Pharmaceuticals Earnings Call Transcript: Q4 2025
2025 revenue reached $172.4M, driven by strong launches of Revuforj and Niktimvo, both exceeding benchmarks. Revuforj expanded into NPM1 AML, while Niktimvo captured 20% of the third-line-plus GVHD market. Robust pipeline and financial position support continued growth.
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimv...
Syndax Announces Participation in March Investor Conferences
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M...
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will repo...
Syndax Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Strong revenue growth and expanding indications for both lead products are driving momentum, with maintenance therapy uptake rising and new clinical milestones expected in 2026. Strategic partnerships and disciplined spending support a clear path to profitability.
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M...
Syndax Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong commercial execution led to rapid revenue growth for two first-in-class oncology drugs, with Revuforj and Niktimvo both surpassing industry benchmarks. Broad clinical programs and robust market adoption position both products for continued expansion and new indications in 2026.
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj ® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approva...
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast ...
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M...
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (r...
Syndax Pharmaceuticals Transcript: Investor Update
Strong commercial and clinical momentum for Niktimvo and Revuforj, with both products exceeding launch expectations and expanding into new indications. Ongoing trials and real-world data support robust efficacy, safety, and future growth, with a focus on earlier lines of therapy and broader patient populations.
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute le...
Syndax Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Three approvals across two drugs have driven rapid commercial success, with Revuforj and Niktimvo setting new benchmarks in their indications. Market penetration is strong, pivotal trials are underway, and both products are expected to drive substantial revenue and profitability, supported by robust real-world and clinical data.
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M...
Syndax Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Two commercial products are driving strong growth, with Revuforj expanding its label and Niktimvo dominating later-line GVHD. Multiple pivotal trials and real-world studies are underway, with robust financial guidance and profitability expected in the next few years.
Syndax Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
Strong commercial launches for two oncology drugs are driving rapid market penetration and profitability, with robust clinical data supporting expansion into new indications and maintenance therapy. Ongoing global trials and a solid financial position underpin a strategy focused on growth and leadership in hematologic malignancies.
Syndax Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Strong commercial launches for two oncology products are driving revenue growth and market penetration, with Revuforj and Niktimvo both expanding into new indications. Maintenance therapy and combination regimens are key growth drivers, while upcoming clinical data and a robust pipeline support a positive financial outlook.
Syndax Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025
Strong commercial launches for two oncology assets are driving rapid growth, with Revumenib expanding into new indications and maintenance therapy, and Niktimba gaining share in chronic GVHD. Frontline clinical trials, innovative endpoints, and a robust cash position set up multiple catalysts over the next 12-18 months.
Syndax Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 revenue grew 21% sequentially, driven by strong launches of Revuforj and Niktimvo. Revuforj's FDA approval in NPM1 mutated AML tripled the addressable market, and both products are on blockbuster trajectories with robust demand and expanding prescriber bases.